- Home
- CGEM vs TYRA Comparison
CGEM vs TYRA Comparison
Compare CGEM & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- TYRA
- Stock Information
- Founded
- CGEM 2016
- TYRA 2018
- Country
- CGEM United States
- TYRA United States
- Employees
- CGEM N/A
- TYRA N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- CGEM Health Care
- TYRA Health Care
- Exchange
- CGEM Nasdaq
- TYRA Nasdaq
- Market Cap
- CGEM 955.5M
- TYRA 812.7M
- IPO Year
- CGEM 2021
- TYRA 2021
- Fundamental
- Price
- CGEM $12.54
- TYRA $15.79
- Analyst Decision
- CGEM Strong Buy
- TYRA Strong Buy
- Analyst Count
- CGEM 7
- TYRA 5
- Target Price
- CGEM $31.67
- TYRA $31.00
- AVG Volume (30 Days)
- CGEM 537.5K
- TYRA 603.1K
- Earning Date
- CGEM 11-07-2024
- TYRA 11-07-2024
- Dividend Yield
- CGEM N/A
- TYRA N/A
- EPS Growth
- CGEM N/A
- TYRA N/A
- EPS
- CGEM N/A
- TYRA N/A
- Revenue
- CGEM N/A
- TYRA N/A
- Revenue This Year
- CGEM N/A
- TYRA N/A
- Revenue Next Year
- CGEM N/A
- TYRA N/A
- P/E Ratio
- CGEM N/A
- TYRA N/A
- Revenue Growth
- CGEM N/A
- TYRA N/A
- 52 Week Low
- CGEM $7.64
- TYRA $10.60
- 52 Week High
- CGEM $30.19
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- CGEM 31.78
- TYRA 35.04
- Support Level
- CGEM $12.04
- TYRA $15.04
- Resistance Level
- CGEM $17.50
- TYRA $16.51
- Average True Range (ATR)
- CGEM 1.12
- TYRA 0.89
- MACD
- CGEM -0.36
- TYRA 0.08
- Stochastic Oscillator
- CGEM 9.15
- TYRA 14.96
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).